2023 NRDL Pricing Implementation and Market Access Outcomes Update

This white paper provides an update on the 2023 National Reimbursement Drug List (NRDL) pricing implementation and market access outcomes. It outlines the ongoing negotiations expected to conclude by November 2024, with pricing results gradually revealed starting January 2025. The document details key takeaways from the 2023 NRDL update, highlighting the primary access pathway for drugs in China, despite the growing private insurance market. It describes the introduction of a new value-rating system by the National Healthcare Security Administration (NHSA) and the optimized review process for innovative therapies. The paper also discusses the negotiation process, including the application, expert review, and final results. It notes the unprecedented negotiation success rate of 85% and the largest formulary expansion in NRDL history, with 121 products included. Furthermore, it examines the impact of price ceilings on oncology drugs and the correlation between population size and pricing outcomes, providing insights into the evolving landscape of drug reimbursement in China.